Keep Going

Together, we’re winning the fight against Afib.

As a leading provider of innovative technologies for the treatment of atrial fibrillation (Afib) and thoracic pain management, cardiothoracic surgeons around the globe count on AtriCure to deliver best in class solutions that can treat even the most complex cases.

First Surgical Afib Indication

AtriCure is the first and only company to receive FDA indication for a surgical ablation device to treat Afib.

Consistently Covered in Medical Journals

Worldwide, numerous peer-reviewed articles are published annually on our products.

Training More Physicians to Treat Afib

More than 2,000 physicians trained on concomitant treatment since the surgical ablation device received FDA approval.

The Coolest Innovation in Pain Management

The first cryo probe indicated for the treatment of both cardiac arrhythmias and the temporary blockage of pain.

The World’s #1 LAA Occlusion Device

AtriClip is the leading epicardial surgical device on the market for LAA occlusion during cardiac surgery, and is the most widely implanted in the world: 170,000 implants and counting.

Visit Us at AATS Week

If you are attending AATS Mitral Conclave 2019, visit us at booth P13. During the AATS Annual Meeting 2019, come see us at booth 1006.

Let's keep going.



First Surgical Afib Indication: The AtriCure Synergy™ Ablation System is FDA approved for the treatment of persistent atrial fibrillation or longstanding persistent atrial fibrillation in patients who are undergoing open concomitant coronary artery bypass grafting and/or valve replacement or repair.
The World’s #1 LAA Occlusion Device: The AtriClip LAA Exclusion System is indicated for the occlusion of the heart’s left atrial appendage, performed under direct visualization and in conjunction with other cardiac surgical procedures. Direct visualization, in this context, requires that the surgeon is able to see the heart directly, with or without assistance from a camera, endoscope, etc., or other appropriate viewing technologies.
The Coolest Innovation in Pain Management: AtriCure’s cryoICE cryoablation probes are sterile, single use devices intended for use in the cryosurgical treatment of cardiac arrhythmias by freezing target tissues, creating an inflammatory response (cryonecrosis) that blocks the electrical conduction pathway. The probe is also intended for use in blocking pain by temporarily ablating peripheral nerves. The probe may be used in conjunction with a standard off-the-shelf nerve stimulation device in applications where precise peripheral nerve location is desired.